Inventor · disambiguated record
Kara Olson
Also filed as: OLSON KARA · OLSON KARA L · OLSON KARA LOUISE
15 granted patents·8 pending applications·465 citations·filing 2008–2025
92Inventor score
Top patents by PatentIndex Score
23 records- 0197US8586713B2Readily isolated bispecific antibodies with native immunoglobulin formatDAVIS SAMUEL·Filed 2010·Granted Nov 19, 2013·422 cites·8 claims
- 0294US11384153B2Bispecific anti-BCMA x anti-CD3 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Jul 12, 2022·16 cites·24 claims
- 0392US11905332B2Antigen-binding molecules that bind CD38 and/or CD28, and uses thereofREGENERON PHARMA·Filed 2021·Granted Feb 20, 2024·3 cites·43 claims
- 0491US11396544B2Bispecific anti-CD28 × anti-CD22 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Jul 26, 2022·8 cites·10 claims
- 0590US11168111B2Readily isolated bispecific antibodies with native immunoglobulin formatREGENERON PHARMA·Filed 2018·Granted Nov 9, 2021·3 cites·24 claims
- 0689US9982013B2Readily isolated bispecific antibodies with native immunoglobulin formatREGENERON PHARMA·Filed 2016·Granted May 29, 2018·3 cites·22 claims
- 0789US9309326B2Readily isolated bispecific antibodies with native immunoglobulin formatREGENERON PHARMA·Filed 2013·Granted Apr 12, 2016·5 cites·19 claims
- 0885US12419282B2Non-human animals expressing humanized CD3 complexREGENERON PHARMA·Filed 2024·Granted Sep 23, 2025·0 cites·20 claims
- 0981US2022389055A1Readily Isolated Bispecific Antibodies with Native Immunoglobulin FormatREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1079US12157758B2Readily isolated bispecific antibodies with native immunoglobulin formatREGENERON PHARMA·Filed 2021·Granted Dec 3, 2024·0 cites·24 claims
- 1177US8268311B2Human GM-CSF antigen binding proteinsKIRCHNER JACQUELINE A·Filed 2008·Granted Sep 18, 2012·5 cites·13 claims
- 1275US12258412B2Nucleic acid molecules encoding bispecific anti-BCMA x anti-CD3 antibodiesREGENERON PHARMA·Filed 2022·Granted Mar 25, 2025·0 cites·20 claims
- 1373US11937587B2Non-human animals expressing humanized CD3 complexREGENERON PHARMA·Filed 2020·Granted Mar 26, 2024·0 cites·19 claims
- 1471US10932455B2Non-human animals expressing humanized CD3 complexREGENERON PHARMA·Filed 2020·Granted Mar 2, 2021·0 cites·28 claims
- 1571US2023174652A1Bispecific Anti-CD28 X Anti-CD22 Antibodies and Uses ThereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1670US12274747B2Compositions and methods for treating cytokine release syndromeREGENERON PHARMA·Filed 2022·Granted Apr 15, 2025·0 cites·33 claims
- 1768US2025223360A1Bispecific anti-cd28 x anti-cd22 antibodies and uses thereofREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1862US2023416396A1Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1961US2023357446A1Compositions and methods for universal tumor cell killingREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2061US2025302949A1Compositions and methods for treating cytokine release syndromeREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2159US2017164588A1Non-human animals expressing humanized cd3 complexREGENERON PHARMA·Filed 2015·Application pending·0 cites
- 2252US8481704B2Nucleic acid molecule encoding human GM-CSF antigen binding proteinsKIRCHNER JACQUELINE A·Filed 2012·Granted Jul 9, 2013·0 cites·7 claims
- 2351US2013259799A1Human gm-csf antigen binding proteinsAMGEN INC·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Kara Olson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →